An optimized engineered bacterium for tyrosinemia type 1 therapy: A multi-species preclinical study
Molecular Therapy · 2026
DOI: 10.1016/j.ymthe.2026.05.024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2026. Verfasst von Peng Gu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathophysiology, Guangdong Provincial Key Laboratory of Proteomics, School of Basic Medical Sciences, Southern Medical University, Guan…. Hauptthemen laut MEDLINE: Tyrosinemias. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province, National Key Research and Development Program of China.
Abstract (Originalsprache)
Hereditary tyrosinemia type 1 (HT1) is a life-threatening metabolic disorder caused by the toxic accumulation of tyrosine and its metabolites. While treatment with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) combined with a strict dietary regimen has improved outcomes, it imposes a significant lifelong burden and is associated with debilitating side effects and incomplete protection. Here, we developed an engineered probiotic with an optimized design, e-EcN-HT, and demonstrated its comprehensive efficacy and safety in HT1 across multiple animal models, including fumarylacetoacetate hydrolase (FAH)-/- mice, FAH-/- rabbits, and Bama minipigs. Our findings indicate that e-EcN-HT not only mitigates multifaceted acute manifestations of FAH-/- mice, including neonatal death and acute liver injury, but also improves chronic liver lesions when combined with NTBC. The therapeutic effect translated successfully to the FAH-/- rabbit model. Moreover, e-EcN-HT administration led to rapid metabolism of orally administered 13C-tyrosine, confirming robust and active tyrosine consumption in pigs. Comprehensive safety assessments across murine and porcine models showed that e-EcN-HT was well tolerated, with no significant adverse effects, systemic dissemination, or detrimental disruption to the resident gut microbiota. Collectively, our multi-species preclinical data underscore the potential of engineered bacteria as a viable therapeutic strategy for HT1 and possibly other metabolic disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathophysiology, Guangdong Provincial Key Laboratory of Proteomics, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China.
- Laboratory Animal Management Center, Southern Medical University, Guangzhou 510515, China.
- Department of Pharmacy, The Seventh Affiliated Hospital of Southern Medical University, Foshan 528244, China.
- Department of Pathophysiology, Guangdong Provincial Key Laboratory of Proteomics, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China; Department of Gastroenterology, Shenzhen Hospital…
- Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
- Department of Pathophysiology, Guangdong Provincial Key Laboratory of Proteomics, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China; Department of Gastroenterology, Digestive Medicin…
Förderung
- National Natural Science Foundation of China
- Basic and Applied Basic Research Foundation of Guangdong Province
- National Key Research and Development Program of China
Zitieren
APA
Gu, P., Zhao, Y., Hu, J., Tian, Y., Zhao, L., Ren, J., Yang, Q., Li, J., He, W., Guo, J., & Chen, P. (2026). An optimized engineered bacterium for tyrosinemia type 1 therapy: A multi-species preclinical study. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2026.05.024
Vancouver
Gu P, Zhao Y, Hu J, Tian Y, Zhao L, Ren J, et al. An optimized engineered bacterium for tyrosinemia type 1 therapy: A multi-species preclinical study. Molecular Therapy. 2026. doi:10.1016/j.ymthe.2026.05.024
BibTeX
@article{Gu2026,
author = {Gu, Peng and Zhao, Yunfei and Hu, Jiajia and Tian, Yuguang and Zhao, Lingyan and Ren, Jingjing and Yang, Qin and Li, Jiaxin and He, Wenhao and Guo, Jiayin and Chen, Peng},
title = {An optimized engineered bacterium for tyrosinemia type 1 therapy: A multi-species preclinical study},
journal = {Molecular Therapy},
year = {2026},
doi = {10.1016/j.ymthe.2026.05.024}
}
EUVIMED